Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose post-transplant cyclophosphamide plus low-dose antithymocyte globulin vs standard-dose regimen for GVHD prevention in unrelated donor PBSC transplantation
ChiCTR2200056979Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2020
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cyclophosphamide and antithymocyte globulin in hematopoietic malignancies (2 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Bone marrow aspiration, Routine blood test and 1 more. Started Aug 2020; status: recruiting.
02
Drugs
cyclophosphamideantithymocyte globulin
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2200056979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056979.